AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15316852 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture using laser needles (optical stimulation method)
Number of subjects: 18
Study 15316852 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 18
Study 11513907 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO short-course chemotherapy
Number of subjects: 646
Study 11513907 — intervention group
Group type: COMPARATOR
Intervention: Russian tuberculosis treatment
Number of subjects: 646
Study 9051390 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I (80 mcg/kg s.c.)
Number of subjects: 43
Study 9051390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8329005 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal
Number of subjects: 8
Study 3570421 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride, 120 mEq/day
Number of subjects: 101
Study 3570421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 29121961 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (physical exercise and cognitive behavioral techniques)
Number of subjects: 160
Study 29121961 — intervention group
Group type: COMPARATOR
Intervention: Pain education program (treatment as usual)
Number of subjects: 160
Study 26099226 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulins (ATG)
Number of subjects: 384
Study 26099226 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab
Number of subjects: 384
Study 24318038 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g/kg for 7 days)
Number of subjects: 23
Study 24318038 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 23
Study 24318038 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 23
Study 24318038 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 23
Study 21374068 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg/day
Number of subjects: 320
Study 21374068 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg/day
Number of subjects: 320
Study 18979504 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan muesli (4.8 g oat beta-glucan)
Number of subjects: 42
Study 18979504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination muesli (4.8 g oat beta-glucan plus 1.4 g stanol as PSE)
Number of subjects: 42
Study 18979504 — intervention group
Group type: COMPARATOR
Intervention: Control muesli (4.8 g control fiber)
Number of subjects: 42
Study 18979504 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan muesli and Combination muesli
Number of subjects: 42
Study 18979504 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE (plant stanol esters)
Number of subjects: 42
Study 17456125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-CHW team intervention
Number of subjects: 530
Study 17456125 — intervention group
Group type: COMPARATOR
Intervention: Standard community care (enhanced prenatal services with nurse home visiting)
Number of subjects: 530
Study 14738235 — intervention group
Group type: EXPERIMENTAL
Intervention: DNK333 (100 mg)
Number of subjects: 19
Study 14738235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11321379 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula based on acid whey without glycomacropeptide (GMP)
Number of subjects: 14
Study 11321379 — intervention group
Group type: COMPARATOR
Intervention: Sweet whey formula with glycomacropeptide (GMP)
Number of subjects: 14
Study 9661678 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) at 2.5 micrograms/kg/hr
Number of subjects: 8
Study 9661678 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) at 4.0 micrograms/kg/hr
Number of subjects: 8
Study 9661678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7923825 — intervention group
Group type: COMPARATOR
Intervention: 5% saline infusion (0.06 ml/kg/h)
Number of subjects: 8
Study 7923825 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol infusion (0.07 ml/kg/h)
Number of subjects: 8
Study 2894902 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.4 mg.kg‐1)
Number of subjects: 67
Study 2894902 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine (0.8 mg.kg‐1)
Number of subjects: 67
Study 2894902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.12 mg.kg‐1)
Number of subjects: 67
Study 2894902 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.07 mg.kg‐1)
Number of subjects: 67
Study 30370837 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 8-week Mindfulness-Based Stress Reduction (MBSR) program
Number of subjects: 110
Study 30370837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study 28155109 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer‐based Group Lifestyle Balance (PGLB) intervention
Number of subjects: 14
Study 25675317 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare treatment (2-4 interview contacts via telephone or face-to-face within the first 3 months after discharge)
Number of subjects: 201
Study 25675317 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 201
Study 23866800 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Number of subjects: 61
Study 21478141 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage stimulation (HVS) with drug therapy
Number of subjects: 40
Study 21478141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound with drug therapy
Number of subjects: 40
Study 21478141 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with drug therapy
Number of subjects: 40
Study 21478141 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings with drug therapy
Number of subjects: 40
Study 21478141 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy only
Number of subjects: 40
Study 21478141 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative HVS with drug therapy
Number of subjects: 40
Study 21478141 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative ultrasound with drug therapy
Number of subjects: 40
Study 21478141 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative LLLT with drug therapy
Number of subjects: 40
Study 21478141 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative compression with drug therapy
Number of subjects: 40
Study 21478141 — intervention group
Group type: COMPARATOR
Intervention: Conservative drug therapy only
Number of subjects: 40
Study 19515730 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FPV/RTV (1400 mg/100 mg twice daily)
Number of subjects: 74
Study 19515730 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV/LPV/RTV (1400 mg/533 mg/133 mg twice daily)
Number of subjects: 74
Study 19515730 — intervention group
Group type: COMPARATOR
Intervention: STD-FPV/RTV (700 mg/100 mg twice daily)
Number of subjects: 74
Study 19515730 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FPV/RTV
Number of subjects: 74
Study 19515730 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV/LPV/RTV
Number of subjects: 74
Study 19515730 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-FPV/RTV and FPV/LPV/RTV
Number of subjects: 74
Study 17368232 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 77
Study 17368232 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 77
Study 17368232 — intervention group
Group type: COMPARATOR
Intervention: Sham feedback therapy
Number of subjects: 77
Study 14999111 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (conjugated equine estrogens 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day)
Number of subjects: 16608
Study 14999111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 14999111 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 16608
Study 14999111 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin with antecedent vaginal bleeding
Number of subjects: 16608
Study 11525858 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat
Number of subjects: 15
Study 11525858 — intervention group
Group type: COMPARATOR
Intervention: Allevyn
Number of subjects: 15
Study 9783966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicated albumin enhanced sonography
Number of subjects: 20
Study 9783966 — intervention group
Group type: COMPARATOR
Intervention: Voiding cystourethrography
Number of subjects: 20
Study 7979842 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional internal medicine clerkship (n=69)
Number of subjects: 163
Study 7979842 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory medicine and ward medicine (n=38)
Number of subjects: 163
Study 7979842 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory clerkship
Number of subjects: 163
Study 7979842 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attitudes towards internal medicine training
Number of subjects: 163
Study 7979842 — intervention group
Group type: EXPERIMENTAL
Intervention: Income potential
Number of subjects: 163
Study 2781008 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan
Number of subjects: 80
Study 2781008 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate sodium meglumine
Number of subjects: 80
Study 2781008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 80
Study 4987898 — intervention group
Group type: EXPERIMENTAL
Intervention: Mite extract (Dermatophagoides pteronyssinus)
Number of subjects: 28
Study 31860455 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pulse width (SPW) stimulation (90 μs)
Number of subjects: 22
Study 31860455 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulse width (LPW) stimulation (210-450 μs)
Number of subjects: 22
Study 31860455 — intervention group
Group type: COMPARATOR
Intervention: Crossover groups (SPW and LPW)
Number of subjects: 22
Study 30606271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20 mg)
Number of subjects: 43
Study 30606271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 28375559 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day-stored autologous RBC transfusion
Number of subjects: 18
Study 28375559 — intervention group
Group type: EXPERIMENTAL
Intervention: 35-day-stored autologous RBC transfusion
Number of subjects: 18
Study 28375559 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 18
Study 28375559 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS stimulation
Number of subjects: 18
Study 28375559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo stimulation with LPS and LTA
Number of subjects: 18
Study 25367835 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings Program (11-week family-focused group preventive intervention)
Number of subjects: 161
Study 25367835 — intervention group
Group type: COMPARATOR
Intervention: Control condition (literature control condition)
Number of subjects: 161
Study 23837278 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (10 mL)
Number of subjects: 60
Study 23837278 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg in 10 mL normal saline)
Number of subjects: 60
Study 21308748 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-trimming of the bladder edges
Number of subjects: 64
Study 21308748 — intervention group
Group type: COMPARATOR
Intervention: Trimming of the bladder edges
Number of subjects: 64
Study 19667972 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 9
Study 19667972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg alprazolam
Number of subjects: 9
Study 19667972 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg alprazolam
Number of subjects: 9
Study 19667972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15863522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 24
Study 15863522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15863522 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P
Number of subjects: 24
Study 15605689 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycin (100 mg)
Number of subjects: 24
Study 11705752 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (up to 0.3 mg po)
Number of subjects: 55
Study 11705752 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg po)
Number of subjects: 55
Study 11705752 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (as low as 0.05 mg)
Number of subjects: 55
Study 11705752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9717652 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of timolol 0.5% and latanoprost 0.001% (comb. 10)
Number of subjects: 139
Study 9717652 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of timolol 0.5% and latanoprost 0.005% (comb. 50)
Number of subjects: 139
Study 9717652 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 139
Study 9717652 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 139
Study 1670445 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 120
Study 1670445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 6843197 — intervention group
Group type: COMPARATOR
Intervention: Technicians dispensing prescriptions
Number of subjects: 900
Study 6843197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists dispensing prescriptions
Number of subjects: 900
Study 6843197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists counseling patients after technicians began dispensing prescriptions
Number of subjects: 900
Study 31561715 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically probable laboratory supported ALS
Number of subjects: 0
Study 31561715 — intervention group
Group type: COMPARATOR
Intervention: Other EEC categories
Number of subjects: 0
Study 31045589 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/d)
Number of subjects: 134
Study 28375792 — intervention group
Group type: EXPERIMENTAL
Intervention: Idracemi, 0.3% cortisol phosphate eye drops twice a day
Number of subjects: 40
Study 28375792 — intervention group
Group type: COMPARATOR
Intervention: Cortivis, 0.3% cortisol phosphate in hyaluronic acid vehicle, twice a day
Number of subjects: 40
Study 28551092 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive treatment
Number of subjects: 125
Study 24066735 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 224
Study 24066735 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call reminders
Number of subjects: 224
Study 24066735 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS + Phone call reminders
Number of subjects: 224
Study 24066735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 224
Study 21841500 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 640 mg/day
Number of subjects: 391
Study 21841500 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/day
Number of subjects: 391
Study 21841500 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/day
Number of subjects: 391
Study 21841500 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (all doses)
Number of subjects: 391
Study 19123865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (ART)
Number of subjects: 978
Study 17161118 — intervention group
Group type: EXPERIMENTAL
Intervention: NETA/EE-24 (24-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g)
Number of subjects: 886
Study 17161118 — intervention group
Group type: EXPERIMENTAL
Intervention: NETA/EE-24
Number of subjects: 886
Study 17161118 — intervention group
Group type: COMPARATOR
Intervention: NETA/EE-21 (21-day regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g)
Number of subjects: 886
Study 15079096 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless aortic bioprosthesis
Number of subjects: 66
Study 15079096 — intervention group
Group type: COMPARATOR
Intervention: Mechanical aortic valve substitute
Number of subjects: 66
Study 11342363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine plus IFN‐alpha
Number of subjects: 810
Study 11342363 — intervention group
Group type: COMPARATOR
Intervention: IFN‐alpha alone
Number of subjects: 810
Study 10188679 — intervention group
Group type: EXPERIMENTAL
Intervention: Petrolatum pretreatment
Number of subjects: 20
Study 7972620 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 32
Study 7972620 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocking drug (Bisoprolol)
Number of subjects: 32
Study 2919797 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 20
Study 2919797 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 20
Study 168645 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (Premarin) 1.25 mg
Number of subjects: 0
Study 168645 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (Premarin) 2.5 mg
Number of subjects: 0
Study 30243803 — intervention group
Group type: EXPERIMENTAL
Intervention: LeucoPatch
Number of subjects: 269
Study 30243803 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 269
Study 28915907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's recorded voice
Number of subjects: 66
Study 28915907 — intervention group
Group type: COMPARATOR
Intervention: Stranger's voice
Number of subjects: 66
Study 26375514 — intervention group
Group type: EXPERIMENTAL
Intervention: CM + CBT (n = 69)
Number of subjects: 116
Study 26375514 — intervention group
Group type: COMPARATOR
Intervention: CBT alone (n = 47)
Number of subjects: 116
Study 26375514 — intervention group
Group type: EXPERIMENTAL
Intervention: CM + CBT
Number of subjects: 116
Study 26375514 — intervention group
Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 116
Study 23051870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 16 weeks
Number of subjects: 32
Study 23051870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tai Chi)
Number of subjects: 32
Study 21681533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg (Group L)
Number of subjects: 90
Study 21681533 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg (Group H)
Number of subjects: 90
Study 21681533 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90
Study 17674017 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 88
Study 17674017 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (Control)
Number of subjects: 88
Study 16549931 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 infusion (n = 6)
Number of subjects: 12
Study 16549931 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (n = 6)
Number of subjects: 12
Study 12759270 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (100 micro g in each nostril)
Number of subjects: 63
Study 12759270 — intervention group
Group type: COMPARATOR
Intervention: Combination of loratadine (10 mg) and montelukast sodium (10 mg) by mouth once daily
Number of subjects: 63
Study 10752815 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/kg)
Number of subjects: 8
Study 10752815 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study 9109607 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iodized oil (100 mg)
Number of subjects: 617
Study 9109607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study 8500312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail/phone recruitment strategy
Number of subjects: 5887
Study 8500312 — intervention group
Group type: EXPERIMENTAL
Intervention: Media recruitment strategy
Number of subjects: 5887
Study 8500312 — intervention group
Group type: COMPARATOR
Intervention: Worksite recruitment strategy
Number of subjects: 5887
Study 8500312 — intervention group
Group type: COMPARATOR
Intervention: Public site recruitment strategy
Number of subjects: 5887
Study 8500312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing monitoring and flexible approach
Number of subjects: 5887
Study 8500312 — intervention group
Group type: COMPARATOR
Intervention: Female screenees
Number of subjects: 5887
Study 3301517 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg isosorbide dinitrate
Number of subjects: 15
Study 3301517 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate
Number of subjects: 15
Study 3301517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3301517 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (both doses)
Number of subjects: 15
Study 3301517 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 15
Study 31073885 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Diet Score
Number of subjects: 6874
Study 31073885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Adherence Score (MEDAS)
Number of subjects: 6874
Study 31073885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-vegetarian dietary pattern
Number of subjects: 6874
Study 31073885 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Healthy Eating Index 2010
Number of subjects: 6874
Study 31073885 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDAS and Prime Diet Quality Score (PDQS)
Number of subjects: 6874
Study 31073885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality dietary indexes
Number of subjects: 6874
Study 28927565 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary Pneumatic Compression Device (SPCD)
Number of subjects: 20
Study 28927565 — intervention group
Group type: COMPARATOR
Intervention: Portable Pneumatic Compression Device (PPCD)
Number of subjects: 20